Key Points
- Rein Therapeutics director Josef Von Rickenbach bought 15,950 shares at $1.05 each, spending $16,747.50 and increasing his holdings by 84.51% to 34,824 shares.
- The company recently beat quarterly earnings expectations, reporting a loss of $0.19 per share versus analysts’ estimate of a $0.49 loss.
- Analysts currently have a Hold consensus on RNTX, with an average price target of $8.00, while the stock was trading around $1.11 and remains well below its 52-week high.
Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) Director Rickenbach Josef Von purchased 15,950 shares of the business's stock in a transaction on Friday, May 22nd. The stock was bought at an average cost of $1.05 per share, for a total transaction of $16,747.50. Following the purchase, the director owned 34,824 shares of the company's stock, valued at approximately $36,565.20. This represents a 84.51% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Rein Therapeutics Stock Performance
Shares of RNTX opened at $1.11 on Friday. Rein Therapeutics Inc. has a twelve month low of $0.95 and a twelve month high of $2.18. The firm's 50 day moving average price is $1.33 and its two-hundred day moving average price is $1.31. The firm has a market cap of $94.95 million, a P/E ratio of -0.58 and a beta of 1.42.
Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.30. On average, sell-side analysts anticipate that Rein Therapeutics Inc. will post -1.63 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Rein Therapeutics to a "sell" rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $8.00.
Read Our Latest Stock Report on RNTX
Institutional Trading of Rein Therapeutics
Institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new stake in shares of Rein Therapeutics in the third quarter worth $35,000. HRT Financial LP bought a new stake in shares of Rein Therapeutics in the fourth quarter worth $38,000. Chicago Partners Investment Group LLC lifted its position in shares of Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company's stock worth $53,000 after purchasing an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Rein Therapeutics in the second quarter worth $68,000. Finally, Jane Street Group LLC bought a new stake in shares of Rein Therapeutics in the fourth quarter worth $72,000. Institutional investors own 90.89% of the company's stock.
Rein Therapeutics Company Profile
(
Get Free Report)
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
